Organon & Co. (OGN)
NYSE: OGN
· Real-Time Price · USD
8.23
-0.49 (-5.62%)
At close: May 06, 2025, 11:38 AM
-5.62% (1D)
| Bid | 8.23 |
| Market Cap | 2.14B |
| Revenue (ttm) | 4.78B |
| Net Income (ttm) | 663.09M |
| EPS (ttm) | 2.88 |
| PE Ratio (ttm) | 2.86 |
| Forward PE | 2.38 |
| Analyst | Hold |
| Ask | 8.24 |
| Volume | 4,561,634 |
| Avg. Volume (20D) | 4,859,386 |
| Open | 8.61 |
| Previous Close | 8.72 |
| Day's Range | 8.19 - 8.66 |
| 52-Week Range | 8.19 - 23.10 |
| Beta | 0.69 |
About OGN
Organon & Co., a health care company, develops and delivers health solutions through a portfolio of prescription therapies in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive. The company's biosimilars portfolio consists of three immunology products, such as Brenzys, Renflexis, and Hadlima, as well as two oncology pr...
Industry Drug Manufacturers - General
Sector Healthcare
IPO Date May 14, 2021
Employees 10,000
Stock Exchange NYSE
Ticker Symbol OGN
Website https://www.organon.com
Analyst Forecast
According to 4 analyst ratings, the average rating for OGN stock is "Hold." The 12-month stock price forecast is $20, which is an increase of 142.87% from the latest price.
Stock ForecastsEarnings Surprise
Organon & has released their quartely earnings
on May 1, 2025:
21 hours ago
-9.07%
Organon shares are trading lower after Morgan Stan...
Unlock content with
Pro Subscription
5 days ago
-26.91%
Organon shares are trading lower after the company reported Q1 financial results and cut its quarterly dividend.
3 days ago · seekingalpha.com
Why The Low Payout Ratio Did Not Stop The Dividend Cut For OrganonOrganon boasted of a sub-33% dividend payout ratio.
